Prostate cancer is one of the largest killers among males worldwide. Until recently, prostate cancer diagnosis has relied on a combination of prostate-specific antigen (PSA) level, digital rectal ...
The role of the prostate cancer antigen 3 (PCA3) assay (Hologic/Gen-Probe) in ruling out prostate cancer in men presenting for a repeat biopsy has been supported by a large American study. However, ...
March 30, 2007 — A new test for prostate cancer, which measures levels of the prostate cancer gene 3 (PCA3) in urine, may be useful in diagnosing prostate cancer in men who have elevated serum levels ...
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group found insufficient evidence to recommend prostate cancer antigen 3 (PCA3) testing to inform decisions for when ...
Currently, early detection of prostate cancer depends on an abnormal digital rectal examination and an elevated prostate-specific-antigen (PSA) level requiring a prostate biopsy, often associated with ...
The test is called a PCa3 test and stands for prostate cancer gene three. Prostate cells have PCA3 genes that make the cells produce a small amount of a particular kind of protein. Prostate cancer ...
Diagnostic combines PCA3 and three other RNAs, including a gene fusion, according to Cancer Research paper. An experimental biomarker test more accurately detects prostate cancer than any other ...
In the European Randomised Study of Screening for Prostate Cancer (ERSPC) trial, PCA3 was assessed as a first line-screening test. 40 While the positive predictive values of a PCA3 score of 10 or ...
Alkaline phosphatase (ALP) normalization and overall survival in patients with bone metastases from castration-resistant prostate cancer (CRPC) treated with radium-223. Germ-line single nucleotide ...
(HealthDay)—Testing for combined urinary PCA3 and TMPRSS2:ERG (T2:ERG) RNA can improve detection of prostate cancer, according to a study published online May 18 in JAMA Oncology. Martin G. Sanda, M.D ...
QUEBEC CITY, May 25, 2012 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR), a Quebec life sciences company that develops and commercializes high-value cancer diagnostic tests, reported that the PROGENSA PCA3 ...
The clinical study leading to FDA approval of the PCA3 test in February of 2012 was a multicenter study from 14 clinical sites. The study included 466 men aged 50 years or older who had at least one ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results